Business
Mesoblast reveals more COVID trials needed, shares tumble – Sydney Morning Herald
The Melbourne biotech has been advised by the US medicines regulator that it will need to run another trial of its COVID-19 treatment…
Stem cell treatments maker Mesoblast faces a new hurdle after the US medicines regulator told the company it would need to run another trial of its COVID-19 treatment before it could apply for emergency approvals.
Shares in the Melbourne biotech fell 15.9…
Continue Reading
-
General14 hours agoTaylor Swift breaks Adele’s record for most album sales in first week
-
General20 hours agoMan charged with murder after alleged assault victim dies in Hervey Bay
-
Noosa News19 hours agoPublic health alert for nitazenes issued after person dies in Queensland
-
Business18 hours agoWhat’s Macquarie’s price target on Mineral Resources shares?